Skip to main content
Home > SciBX > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Cancer target selection pressure

    An Institute of Cancer Research team has developed a computational algorithm that hones in on cancer targets with the desired mix of biological validation and druggability. The approach could help prioritize targets.

    Published on 2/14/2013
  • Figure 1: Business areas covered by 2012 public-private partnerships

    2012 gets a new deal Figure 1. Business areas covered by 2012 public-private partnerships. Breakdown of therapeutic areas covered by public-private partnerships (PPPs; I) and seed or series A financings (III) in 2012…

    Published on 2/7/2013
  • Figure 2: Regional breakdown of public-private partnerships in 2012 and 2011

    2012 gets a new deal Figure 2. Regional breakdown of public-private partnerships in 2012 and 2011. Number of disclosed public-private partnerships (PPPs) worldwide in the respective year. Data includes double …

    Published on 2/7/2013
  • Figure 3: Further regional breakdown of public-private partnerships

    2012 gets a new deal Figure 3. Further regional breakdown of public-private partnerships. Regional breakdown of companies and institutions involved in public-private partnerships (PPPs) in the top five U.S. states (I…

    Published on 2/7/2013
  • Table 1: Largest series A financing rounds for companies founded in 2012

    2012 gets a new deal Table 1. Largest series A financing rounds for companies founded in 2012. Four of the largest series A rounds for biotechs founded in 2012 went to companies based in the San Francisco Bay Area. …

    Published on 2/7/2013
  • Table 2: Leaders in the number of public-private partnerships

    2012 gets a new deal Table 2. Leaders in the number of public-private partnerships. The NIH and European Commission took the top positions with respect to the number of disclosed public-private partnerships (PPPs) in…

    Published on 2/7/2013
  • Table 3: Top public-private partnerships in 2012 by value

    2012 gets a new deal Table 3. Top public-private partnerships in 2012 by value. Two of the five largest 2012 public-private partnerships (PPPs) without direct government support were valued at $100 million or more. …

    Published on 2/7/2013
  • 2012 gets a new deal

    SciBX's second annual global analysis of public-private partnerships and early stage venture financing activity reveals that government institutions are taking a significant role in forming and funding PPPs, and …

    Published on 2/7/2013
  • CRISPR genome editing

    Five separate research teams have developed a Cas9 endonuclease-based method for sequence-specific genome modification. Although the approach is technically more straightforward than existing methods, its specificity …

    Published on 1/31/2013
  • In silico drug design

    A Dundee-UNC team has created a computational algorithm that mines medicinal chemistry literature to predict new ligands that bind specific combinations of GPCRs. Ex Scientia was spun out of Dundee to commercialize the …

    Published on 1/24/2013
  • HER2's new mutations

    Washington University in St. Louis School of Medicine researchers have used next-generation sequencing to identify mutations in HER2 that are missed by standard screening tests. Based on the findings, the researchers …

    Published on 1/17/2013
  • mAb about FGF21

    Amgen researchers have developed an antibody that mimics fibroblast growth factor 21 and has antidiabetic effects in monkeys. The findings cap a year of advances that have greatly increased understanding of the protein'…

    Published on 1/10/2013
  • Figure 1: FGF21 gets detailed

    mAb about FGF21 Figure 1. FGF21 gets detailed. Researchers from Amgen Inc. and Roche's Genentech Inc. unit have separately published studies that suggest using antibodies to mimic fibroblast growth factor 21 (FGF21) …

    Published on 1/10/2013
  • Translating mRNA vaccines

    CureVac and the Friedrich Loeffler Institute have in vivo evidence that an mRNA-based vaccine can prevent influenza A infection. The results provide proof of concept for the company's vaccine platform in infectious …

    Published on 12/20/2012
  • Translating autism

    Researchers at McGill University have mouse data showing a causal link between eIF4E-mediated translational dysregulation and autism-related deficits. The group also corrected the dysregulation-and the associated …

    Published on 12/13/2012
  • A current affair in MS

    A European team has used the diabetes drug glibenclamide to block inflammation-induced neurodegeneration in mice. The team plans to test the nonspecific inhibitor of the cationic channel TRPM4 in an investigator-led …

    Published on 12/6/2012
  • Multitasking E selectin

    Researchers at the Mater Medical Research Institute, The University of Queensland and GlycoMimetics have mouse data showing that E selectin antagonists can alleviate side effects of chemotherapy brought about by …

    Published on 11/29/2012
  • Box 1: More repurpose

    Multitasking E selectin Box 1. More repurpose. An Indiana University School of ­Medicine team has shown that the diabetes drug Januvia sitagliptin can enhance the recovery of hematopoietic stem and progenitor cells …

    Published on 11/29/2012
  • Box 1: SciBX innovation summits launched

    Cover Story: Bringing macrocycles full circle Box 1. SciBX innovation summits launched. This week, SciBX is publishing the first Roadmap for Innovation resulting from a SciBX Summit on Innovation in Drug Discovery…

    Published on 11/15/2012
  • Figure 1: Recent company and partnership formation trends in the macrocycle space

    Cover Story: Bringing macrocycles full circle Figure 1. Recent company and partnership formation trends in the macrocycle space. Although company formation in the macrocycle space has been relatively steady since …

    Published on 11/15/2012
  • Bringing macrocycles full circle

    The first SciBX Summit on Innovation in Drug Discovery & Development, held in Boston in September, addressed the opportunity afforded by macrocycles and constrained peptides to open up vast new therapeutic target space,…

    Published on 11/15/2012
  • Turning lupus against cancer

    Researchers at Yale have found that a lupus-related autoantibody sensitizes cancer cells to DNA-damaging radiation and chemotherapy. The antibody, which has already proven safe in a clinical trial in SLE, may be …

    Published on 11/8/2012
  • Revving up glycolysis

    A trio of papers has provided new hints on how best to use activators of PKM2, a target involved in cancer cell metabolism. Astex is using its findings to steer an early stage PKM2 program, whereas Agios is remaining …

    Published on 11/1/2012
  • Melanoma's hidden act

    German researchers have shown that melanoma cells can acquire resistance to adoptive T cell transfer therapies by dedifferentiating themselves to hide antigens. The group now is trying to circumvent this resistance …

    Published on 10/25/2012
  • Figure 1: Resistance to adoptive T cell therapy via dedifferentiation

    Melanoma's hidden act Figure 1. Resistance to adoptive T cell therapy via dedifferentiation. As reported by Landsberg et al., melanoma cells can undergo inflammation-induced dedifferentiation. The process is a …

    Published on 10/25/2012

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993